ABSTRACT
INTRODUCTION

53
Inflammatory bowel diseases, such as ulcerative colitis (UC) and Crohn's disease (CD), are aminosalicylates, and biologics to inhibit mucosal immune responses and production of 61 proinflammatory cytokines (6). While each of these treatment approaches can be of benefit, 62 they also have significant drawbacks in terms of the occurrence of side effects, lack of 63 efficacy, and high cost (42). Thus, more effective, and safer, drugs to treat colitis are much 64 needed.
65
Epithelial cells lining the colonic lumen play a key role in IBD pathogenesis (28, 36) . One of 66 the primary physiological roles of the epithelium is to act as an innate barrier against the 67 uptake of luminal toxins and pathogens. There are several components to this barrier, shown to have the capacity to promote epithelial cytokine release, including bacterial toxins 73 and cell wall components, viral RNA, and bile acids, all of which are altered in the setting of 74 gut inflammation (8, 26, 27) . Thus, given its central role in the development of colitis, the 75 epithelium is currently receiving a great deal of interest as a target for the development of 76 new treatments (28, 42) .
77
Ursodeoxycholic acid (UDCA) is a naturally-occurring secondary bile acid, produced in the 78 colon by bacterial metabolism of the primary bile acid chenodeoxycholic acid (CDCA).
79
UDCA is considered to be unique among bile acids as it has long been recognized to have 80 broad-ranging protective actions. Indeed, UDCA is often referred to as the "therapeutic" bile 81 acid as it has been used for centuries in Traditional Chinese Medicine, as a component of 82 bear bile, to treat diverse maladies, such as failing eyesight, intestinal malaise, impotency, 83 and fever (10). More recently, in Western medicine, UDCA has been used to treat liver 84 inflammation and cholestasis (24, 47) , and currently it is also under investigation for a 85 number of conditions, including neurological, ocular, cardiovascular, and metabolic disorders 86 (45). Importantly, unless it is used at high doses (9), UDCA is a safe drug with few side 87 effects. While its mechanisms of action are not well-defined, it is believed that the therapeutic 88 properties of UDCA are largely due to its anti-inflammatory and cytoprotective actions (5, 89 45). The biological actions of UDCA have been mostly studied in the liver, where it has been 90 shown to exert immunomodulatory and anti-apoptotic actions, and to prevent cytokine release 91 (7, 33, 34, 37 
RESULTS
157
UDCA inhibits pro-inflammatory cytokine release from colonic epithelial cells: First, we Poly I:C-stimulated IFN-γ release ( Figure 1D ), or that of IL-12p70 and GM-CSF (data not 166 shown).
167
UDCA exerts protective effects in the DSS model of mucosal inflammation: Next, we 168 went on to examine the effects of UDCA in the DSS mouse model of mucosal inflammation.
169
The DSS model is considered to be a particularly good model for studying mucosal 170 inflammation occurring as a consequence of disrupted epithelial barrier function (31, 48).
171
Inclusion of 2.5% DSS in the drinking water of C57/BL6 mice led to a reduction in body 
6-MUDCA is not protective against DSS-induced colonic inflammation: In humans,
186
UDCA is known to be metabolised to LCA in the colon and GC-MS analysis of the caecal 187 contents revealed that this is also the case in mice ( Figure 4A ). Thus, we hypothesised that release from 378 ± 108 pg/ml in controls to 236 ± 59 pg/ml (n = 3; p ≤ 0.01), indicating its 196 effects are not cell line-specific. However, despite its capacity to prevent colonic epithelial 197 cytokine secretion in vitro, in contrast to UDCA, 6-MUDCA was not protective against induced mucosal inflammation in vivo, as assessed by DAI measurements ( Figure 4C ).
199
Similarly, 6-MUDCA did not prevent weight loss or colon shortening in response to DSS 200 treatment. Body weight was reduced to 94.8 ± 0.5% of controls in response to 201 compared to 90.0 ± 2.1% in 6-MUDCA-treated mice, whereas colon length in DSS-treated 202 mice was 59.3 ± 1.5 mm compared to 57.7 ± 1.5 mm in those co-treated with 6-MUDCA.
203
This lack of efficacy of 6-MUDCA was contrary to our original hypothesis, and suggest that 204 bacterial metabolism of UDCA is necessary for it to exert its protective effects in vivo. of LCA (0.1 -10 μM) and TNF-α secretion into the bathing medium was measured.
211
Interestingly, we found that LCA treatment was considerably more effective than UDCA, 212 practically abolishing poly I:C-induced TNF-α release ( Figure 5A and c.f. Figure 1A ).
213
Furthermore, the effects of LCA were not specific to TLR3 activation by Poly I:C, since the 3), while ALT levels were determined to be < 6 U/L in all treatment groups. function.
355
In conclusion, our studies support the hypothesis that UDCA may be useful as a new therapy 
